文章摘要

文章信息/Info

Title:: Effect of Pravastatin on plasma levels of hs CRP, ET in elderly patients with coronary heart disease and its nonlipid function

作者:: 钟萍; 陈姗; 四川省医学科学院四川省人民医院干部医疗科心血管病房，四川成都 610072

Author(s):: ZHONG Ping; CHEN Shan; Department of Cardiology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China

关键词:: 普伐他汀; 冠状动脉疾病; C反应蛋白; 内皮素; 非调脂作用

Keywords:: Pravastatin; coronary disease; C-reactive protein; endothelial; non-lipid mechanism

分类号:: R972

DOI:: -

文献标识码:: A

摘要:: 目的观察老年冠心病患者使用普伐他汀治疗8周后，血脂、高敏C反应蛋白（ hs CRP），内皮素（Endothelial, ET）的变化。方法对42例伴有高脂血症的老年冠心病患者每日服用10 mg普伐他汀8周，测定其服药前后血脂［总胆固醇（TC）、三酰甘油（TG），低密度脂蛋白胆固醇（LDL-C），高密度脂蛋白胆固醇（HDL-C）］，hs CRP, ET水平并做统计学分析。结果普伐他汀可有效地降低老年冠心病伴高脂血症患者血脂TC、TG、LDLC和hs CRP、ET（P<0.01，P<0.05），HDL-C有较显著升高（P<0.05），而且普伐他汀引起的血hs CRP、ET的降低分别与TC (r=0.196；r=0.135 )、LDL-C（r=0.227; r=0.176，）、TG（r=0.145 ; r=0.304，P=0.05）的下降之间无相关关系。结论老年冠心病患者服用普伐他汀治疗后，可明显控制血浆hs CRP、ET水平，具有独立于降脂作用之外的抑制炎症，改善内皮功能，稳定斑块的作用。

Abstract:: AIM To observe the changes of plasma levels of high sensitive Creactive protein (hs CRP) and endothelial (ET) following 8week administration of Pravastatin in elderly patients with coronary heart disease (CHD). METHODS Fortytwo elderly patients with CHD and hyperlipidemia were treated with Pravastatin for 8 weeks. Before and after the treatment, the plasma levels of TC, LDLC, HDLC, TG, hs CRP and ET were detected and compared. RESULTS After 8 weeks of treatment, the plasma levels of TC, TG, LDLC, hs CRP and ET were significantly decreased (P<0.01, P<0.05) while HDLC increased (P<0.05). There was no relation between the decreasing values of TC, hs CRP and ET and those of TC (r=0.196; r=0.135 ), LDLC (r=0.227; r=0.176 ) and TG (r=0.145; r=0.304 P=0.05). CONCLUSION HMGCOA reductase inhibitors can reduce the levels of inflammatory factors and they may have some nonlipid effects on the inhibitive activities of inflammatory factors, improving the function of vascular endothelium, which may promote the stabilization of atherosclerotic plaque, independent of lipidlowering effects.

参考文献/References

［1］ Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol in 4444 patients with coronary heart disense: the scandinavian simvastatin survival study (4S)［J］. Lancet, 1994,344（8934）: 1383-1389.

［2］ Bickel C, Rupprecht HJ, Blankenberg S, et al. Relation of markers of inflammation (Creactive protein, fibrinogen, von willebrand factor and leukocyto count ) and statin therapy to longterm mortality in patients with angiographically proven coronary artery disease［J］. Am J cardiol, 2002, 89(8): 901-908.

［3］ Ridker PM, Rifai N, Pfeffer MA, et al. Inaflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels［J］. Circulation, 1998, 98(9): 839-844.

［4］ Kuller LH,Tracy RP,Shaten J,et al. Relation of Creactive protein and coronary heart disease in the MRFIT neated caseControl studymultiple risk factor intervention trial［J］. Am J Epidemiol, 1996, 144(6): 537-547.

［5］ Ueda S,Ikeda U,Yamamoto K,et al. Creactive protein as a predictor of cardiac rupture after acute myocardial infarction［J］. Am Heart J, 1996, 131(5): 857-860.

［6］钟萍，舒燕，蔡力. 冠心病与C反应蛋白［J］.四川医学，2001，22(5)：437-438.

［7］ Yanagisawa M, Kurihara H, Kimura s, et al. A novel potent vasconstrictor peptided produced by vascular endothelial cells［J］. Nature，1988, 332(6163): 411-415.

［8］ Tsiara S, Elisaf M, Mikhailidrs DP. Early vascular benefits of statin therapy［J］. Curr Med Res Opin, 2003, 19(6): 540.

［9］ Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhersion molecule during atherogensis［J］. Science, 1991, 251(4995): 788-791.

［10］Musial J, Undas A, Gajewski P, et al. Autiinflammation effects of Simvastatin in subjects with hypercholesterolemia［J］. Int J Cardiol, 2001, 77(2-3):247-253.

我们的网站为什么显示成这样？

普伐他汀的非调脂作用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics